AMLX

#2023
Amylyx Pharmaceuticals, Inc. Common Stock
17.12 USD
+1.18%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
17.12
17.12
Intervallo Annuale
3.79
17.49
Variazione giornaliera
+1.18%
Variazione Mensile
+20.65%
Variazione di 6 mesi
+7.47%
Variazione Annuale
+344.68%
Chiusura Precedente
16.92
Apertura
17.12
Bid
Ask
Minimo
17.12
High
17.12
Volume
78
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
  • Market Capitalization 1.89 B
  • Employee 136
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-7.9
Rapporto prezzo/fatturato
—

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Notizie